Jin Suk Park

Jin Suk Park

Auto-generated profile, based on publicly available information

Jin Suk Park

Memorial Sloan Kettering Cancer Center 1 Cancer Biology and Genetics Program, Sloan Kettering Institute New York, New York

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Effective treatment for metastatic cancer has remained elusive because of the persistence of drug-resistant metastasis stem cells (MetSC) that drive relapse. MetSCs are tumor cell subpopulations enriched for their ability to reinitiate and sustain metastatic growth, displaying phenotypic plasticity and resistance to chemotherapy. These cells express the L1 cell adhesion molecule (L1CAM), a transmembrane protein detected in numerous human solid tumor types and at multiple disseminated organ sites. As a selective surface marker of MetSCs, L1CAM is a promising candidate for molecularly targeted drugs aimed at eliminating metastases, yet strategies to date have not achieved clinical success. In this study, we develop antibody–drug conjugates (ADC) to deliver highly toxic PNU-159682 payloads to L1CAM-expressing cells. We report the generation of monoclonal antibodies (mAb) with high binding affinity, specificity, and selectivity for the human L1CAM extracellular domain. Optimized L1CAM-targeting mAbs were conjugated to PNU-159682 to generate ADC variants with both cleavable and noncleavable linkers, with an average drug–antibody ratio of four. ADCs derived from three antibodies targeting various epitopes of the L1CAM extracellular portion potently killed cells exhibiting varying levels of surface L1CAM expression. L1CAM ADCs given as monotherapy resulted in robust tumor control and extended survival in mice harboring subcutaneous L1CAM+ xenografts or L1CAM+ lung metastases from triple-negative basal breast cancer and lung adenocarcinoma. Safety analyses with mouse cross-reactive antibodies indicate a feasible therapeutic window. Our findings offer strong proof of concept to support the preclinical development of these novel L1CAM ADCs as therapeutic agents for advanced solid tumors.

1 June 2026
Verified
Other
Open access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Supplementary Figure S2. In vivo clinical chemistry assessment of mice treated with L1CAM ADCs

1 June 2026
Verified
Other
Open access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Supplementary Table S2. Protein sequences of L1CAM antibodies

1 June 2026
Verified
Other
Open access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Supplementary Figure S1. Safety assessment of in vivo L1CAM ADC treatments

1 June 2026
Verified
Other
Open access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Supplementary Table S1. Binding profile of candidate L1CAM mAbs

1 June 2026
Verified
Other
Open access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Effective treatment for metastatic cancer has remained elusive because of the persistence of drug-resistant metastasis stem cells (MetSC) that drive relapse. MetSCs are tumor cell subpopulations enriched for their ability to reinitiate and sustain metastatic growth, displaying phenotypic plasticity and resistance to chemotherapy. These cells express the L1 cell adhesion molecule (L1CAM), a transmembrane protein detected in numerous human solid tumor types and at multiple disseminated organ sites. As a selective surface marker of MetSCs, L1CAM is a promising candidate for molecularly targeted drugs aimed at eliminating metastases, yet strategies to date have not achieved clinical success. In this study, we develop antibody–drug conjugates (ADC) to deliver highly toxic PNU-159682 payloads to L1CAM-expressing cells. We report the generation of monoclonal antibodies (mAb) with high binding affinity, specificity, and selectivity for the human L1CAM extracellular domain. Optimized L1CAM-targeting mAbs were conjugated to PNU-159682 to generate ADC variants with both cleavable and noncleavable linkers, with an average drug–antibody ratio of four. ADCs derived from three antibodies targeting various epitopes of the L1CAM extracellular portion potently killed cells exhibiting varying levels of surface L1CAM expression. L1CAM ADCs given as monotherapy resulted in robust tumor control and extended survival in mice harboring subcutaneous L1CAM+ xenografts or L1CAM+ lung metastases from triple-negative basal breast cancer and lung adenocarcinoma. Safety analyses with mouse cross-reactive antibodies indicate a feasible therapeutic window. Our findings offer strong proof of concept to support the preclinical development of these novel L1CAM ADCs as therapeutic agents for advanced solid tumors.